Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Population-based study of targeted therapy use and outcomes in renal cell carcinoma in the Netherlands
NL-OMON35060Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sunitinib, sorafenib, temsirolimus, bevacizumab and interferon alfa in renal cell carcinoma (RCC) and kidney cancer, sponsored by Radboud University Medical Center. Started Mar 2011; status: recruiting.
02
Drugs
sunitinibsorafenibtemsirolimusbevacizumabinterferon alfa
03
Conditions
renal cell carcinoma (RCC)kidney cancer
Beyond the preview
Go deeper on NL-OMON35060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35060.